Status:
COMPLETED
The Plasma Metabolomics Profiling of Primary Aldosteronism
Lead Sponsor:
Third Military Medical University
Conditions:
Primary Aldosteronism
Essential Hypertension
Eligibility:
All Genders
18-80 years
Brief Summary
Primary aldosteronism (PA), characterized by overt renin-independent aldosterone production, is the most common form endocrine hypertension. Compared with blood pressure-matched cases of essential hyp...
Eligibility Criteria
Inclusion
- According to 2010 Chinese guidelines for the management of Essential hypertension (EH), EH was defined as systolic blood pressure (SBP) ≥140 mm Hg, diastolic blood pressure (DBP) ≥90 mm Hg, and use of antihypertensive medicine within 2 weeks and excluded from PA through ARR or confirmatory testing.
- Patients were confirmed to be diagnosed with Primary aldosteronism (PA) in accordance with the Endocrine Society Clinical Practice Guideline criteria. Patients with an aldosterone-to-renin ratio (ARR) \> 3.7 (ng/dL) further conformed with one of the following confirmatory tests: saline infusion test or captopril-inhibition test. Adrenal CT scans and Adrenal venous sampling (AVS) were performed for PA subtype classification.
- Patients with idiopathic hyperaldosteronism (IHA) were determined based on the absence of obvious adenoma on adrenal CT and bilateral aldosterone overproduction.
- Patients with aldosterone-producing adenoma (APA) were identified based on macroadenoma \>1 cm on adrenal CT, unilateral hypersecretion of aldosterone, and pathological confirmation.
- Signed informed consent and agreed to participate in this study.
Exclusion
- other subtypes of secondary hypertension, including renal hypertension, renovascular hypertension, and adrenal hypertension (i.e., pheochromocytoma and Cushing syndrome).
- adrenal cortical carcinoma
- acute infection at the time of assessment
- severe cardiovascular or cerebrovascular disease, liver or renal dysfunction, tumors, autoimmune disease or mental disorders.
- history of adrenalectomy
- alcohol abuse or pregnancy
Key Trial Info
Start Date :
August 15 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 19 2023
Estimated Enrollment :
95 Patients enrolled
Trial Details
Trial ID
NCT06500000
Start Date
August 15 2022
End Date
May 19 2023
Last Update
July 15 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
China Chongqing The third hospital affiliated to the Third Millitary Medical University
Chongqing, Chongqing Municipality, China, 400042